Neumora Therapeutics Analyst Ratings
Neumora Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/08/2023 | 86.05% | JP Morgan | $21 → $20 | Maintains | Overweight |
| 10/10/2023 | 95.35% | JP Morgan | → $21 | Initiates Coverage On | → Overweight |
| 10/10/2023 | 67.44% | B of A Securities | → $18 | Initiates Coverage On | → Buy |
| 10/10/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 10/10/2023 | 104.65% | Guggenheim | → $22 | Initiates Coverage On | → Buy |
| 10/10/2023 | 123.26% | RBC Capital | → $24 | Initiates Coverage On | → Outperform |
| 10/10/2023 | 141.86% | Stifel | → $26 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/08/2023 | 86.05% | 摩根大通 | 21 美元 → 20 美元 | 維護 | 超重 |
| 2023 年 10 月 10 日 | 95.35% | 摩根大通 | → 21 美元 | 啓動覆蓋範圍開啓 | → 超重 |
| 2023 年 10 月 10 日 | 67.44% | B of A 類證券 | → 18 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2023 年 10 月 10 日 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 2023 年 10 月 10 日 | 104.65% | 古根海姆 | → 22 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2023 年 10 月 10 日 | 123.26% | 加拿大皇家銀行資本 | → 24 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2023 年 10 月 10 日 | 141.86% | Stifel | → 26 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的目標價格是多少？
The latest price target for Neumora Therapeutics (NASDAQ: NMRA) was reported by JP Morgan on November 8, 2023. The analyst firm set a price target for $20.00 expecting NMRA to rise to within 12 months (a possible 86.05% upside). 7 analyst firms have reported ratings in the last year.
摩根大通於2023年11月8日公佈了Neumora Therapeutics（納斯達克股票代碼：NMRA）的最新目標股價。該分析公司將目標股價定爲20.00美元，預計NMRA將在12個月內升至12個月內（可能上漲86.05％）。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的最新分析師評級是多少？
The latest analyst rating for Neumora Therapeutics (NASDAQ: NMRA) was provided by JP Morgan, and Neumora Therapeutics maintained their overweight rating.
摩根大通對Neumora Therapeutics（納斯達克股票代碼：NMRA）的最新分析師評級由摩根大通提供，Neumora Therapeutics維持增持評級。
When is the next analyst rating going to be posted or updated for Neumora Therapeutics (NMRA)?
Neumora Therapeutics（NMRA）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neumora Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neumora Therapeutics was filed on November 8, 2023 so you should expect the next rating to be made available sometime around November 8, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Neumora Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Neumora Therapeutics的最新評級是在2023年11月8日公佈的，因此您應該預計下一個評級將在2024年11月8日左右公佈。
Is the Analyst Rating Neumora Therapeutics (NMRA) correct?
分析師對Neumora Therapeutics（NMRA）的評級是否正確？
While ratings are subjective and will change, the latest Neumora Therapeutics (NMRA) rating was a maintained with a price target of $21.00 to $20.00. The current price Neumora Therapeutics (NMRA) is trading at is $10.75, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Neumora Therapeutics（NMRA）評級維持不變，目標股價爲21.00美元至20.00美元。Neumora Therapeutics（NMRA）目前的交易價格爲10.75美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。